Levamisole prevents serious adverse events in loiasis patients with high Micro Filarial Densities
Using electron microscopy images, the researchers visualize the dendritic spines (yellow) with their spine apparatus (red) and the synapse terminal buttons (blue).
CREDIT
Source: Andreas Vlachos
Individuals with high Loa loa micro filarial densities (MFD) are at risk of serious adverse events (SAEs) after Ivermectin treatment. Pretreatment with drugs that gradually reduce Loa MFD below the risk threshold may aid in the prevention of these SAEs. A new study shows that a single 2.5 mg/kg dose of levamisole results in a promising transient reduction in Loa loa MFD.
This study was conducted by Jérémy T Campillo and team with the objective to evaluate the safety and efficacy of levamisole. The findings of this study were published in Infectious Diseases Society of America on 15th October, 2021.
In the Republic of the Congo, a double-blind, randomized, placebo-controlled MFD-ascending trial was conducted. The participants were divided into three groups based on their pretreatment MFD and levamisole dose (Cohort 1: 1.0 kg and 1.5 mg/kg, Cohorts 2 and 3: 2.5 mg/kg). The first week's safety outcomes were the occurrence of SAE and the frequency of AE. MFD reduction from baseline and proportions of individuals with at least 40% and 80% MFD reduction at day 2 (D2), D7, and D30 were the efficacy outcomes.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.